Status:
COMPLETED
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsy, Partial
Eligibility:
All Genders
Up to 16 years
Phase:
PHASE3
Brief Summary
Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until L...
Eligibility Criteria
Inclusion
- Have completed Study N151, or any other applicable pediatric trials of Levetiracetam (Keppra®)
- Be a patient for whom the treatment of Levetiracetam (Keppra®) would be of potential benefit such that the patient/parent(s)/legal guardian and the Investigator agree to continue treatment.
Exclusion
- Not be on a ketogenic diet (during the course of this study).
- Not have seizures too close together to accurately count (i.e., the patient's seizures must be countable).
Key Trial Info
Start Date :
January 26 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 25 2006
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT00150709
Start Date
January 26 1998
End Date
January 25 2006
Last Update
February 9 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.